Ardelyx regains tenapanor rights from AZ, raises $77.8M

By BC Staff | Jun 4, 2015 | 2:25 AM GMT

Ardelyx Inc. (NASDAQ:ARDX) climbed $4.25 (40%) to $14.95 on Wednesday after it reacquired rights to tenapanor ( AZD1722) from AstraZeneca plc (LSE:AZN NYSE:AZN), unveiled new candidate RDX022 to treat hyperkalemia and raised $77.8 million in a private placement led by New Enterprise Associates.